1. Scrip
  2. >>Conferences
  3. >>ESMO

ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

 
• By Alexandra Shimmings

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

Sagrada Familia, Barcelona
• Source: Shutterstock

Early development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candidates at least.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESMO

ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

 
• By Alexandra Shimmings

J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.    

ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

 
• By Alexandra Shimmings

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs

 
• By Andrew McConaghie

The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.

ESMO 24: Bayer Prostate Drugs Old And New Deliver On Survival

 
• By Kevin Grogan

The German group's goal of expanding Nubeqa into wider prostate cancer patient populations has probably been reached with the results from the Phase III ARANOTE study, while a combination of its older product Xofigo and Pfizer and Astellas’ Xtandi is set to become standard of care for another subset.

More from Conferences

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 
• By Jessica Merrill

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.